||EPS - Basic
||Market Cap (m)
IP Group Share Discussion Threads
Showing 1226 to 1248 of 1250 messages
|Oh well at least I die rich from shorting instead lol
Funny enough I had a secondary target of 140 but elected to fully close out in my primary target of around 150.
I would not be surprised one bit to see the 140 you mention|
|The H&S shoulder patterns both target historical support at 140.
Mr bd, unfortunately, the company that was working on the treatment that would have saved your life was unable to complete its research, due to it being shorted out of business.
There's nothing we can do...|
|Well closed my short today nice profit again. 15% return on the trade.|
|I think I like the www.parkwalkadvisors.com acquisition but would like to know how many investments are common to both IPO and ParkWalk and how many individual companes there are in the portfolio now.|
|Broker still keen on these and their investments. hope he's proved right.|
|At birth when blood group taken.
Future tracking of disease and mental health vs sequence.
Very useful info.|
|"benchmark" hmm ok individual benchmark? Built up from DNA testing say at birth, every visit to hospital and or GP?
Could have some very interesting effects on crime, social services, health care globally and nationally. Fascinating.|
|Just give it time and it will get there.
As for "sifting/deteriorating information" that is easier to handle if you have a benchmark known accurate position to compare to.|
|No holding at the moment.
Did anyone else hear BBC Radio 4's interview with Nanopores MD(Dr Gordon Sanghera)?
His arguments for the adoption of the DNA, Virus and Bacteria self assessment diagnosis products sounds persuasive. Verging on too good to be true?
I understand DNA and RNA is very messy, unique to each person and potentially full of false and constantly shifting/deteriorating information. I would love the products to work but think some caution should be exercised when day dreaming of potential outcomes?|
|Bamboo2 FYI I have an investment broker who initially put me in these at 25p back in 2011 as the price increased he sold chunks off, ( I mimicked him but added as the price increased & did very well). He has held a chunk for me since but about 2-3 weeks ago added to the position @ £1.58 (first purchase since the initial one), I guess they are expecting a good news flow in the near future.|
|Steptoe, since the price has come back to retest the neckline of the INVH&S, I might have to consider buying back!|
|Bamboo thank you for sharing your chart & views, interesting target £1.90. I shall use that as my initial goal|
|Steptoe, agreed, I'm a bit impatient. I probably needed the capital for another trade.
Looks like this will carry on with a confirmed INVH&S to approx 190 next.|
|Think you gave up a tad early Bamboo, still hanging in here myself|
|Gave up on my trade here today. Took a few percent, but seller at around 160.|
|FOR RELEASE ON 16 December 2016
IP Group plc acquires Parkwalk, the UK's largest EIS growth fund manager focused on university spin-outs
IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, is delighted to announce that it has agreed to acquire Parkwalk Advisors Ltd ("Parkwalk"), the UK's leading university spin-out focused EIS fund manager, for an initial consideration of GBP10m.
Founded in 2009, Parkwalk is the largest EIS growth fund manager focused on university spin-outs, having raised over GBP100m to date with the majority of funds coming from leading private wealth platforms and having backed over 60 companies across its managed funds since inception. In 2016 alone, Parkwalk committed over GBP40m to UK university spin-outs and has been a long-term co-investment partner of IP Group, having co-invested over GBP17m in 14 investment rounds during 2015/2016. Parkwalk is a profitable business and will be immediately accretive to IP Group's operating results.
Parkwalk has significant assets under management, an experienced team and strong links to many of IP Group's existing university partners. Its investment vehicles include the evergreen Parkwalk Opportunities Fund, the University of Cambridge Enterprise Funds, the University of Oxford Innovation Funds and the University of Bristol Enterprise Funds.
Parkwalk will retain its existing investment team and investment decision-making independence post-acquisition.
Alan Aubrey, Chief Executive of IP Group, said: "Parkwalk is a great strategic fit for IP Group being the market leader in the sector with fast growing assets under management run by an experienced team with an excellent track record. The acquisition reinforces IP Group's access to a diversified pool of capital for co-funding the earlier stages of the portfolio while providing a profitable and growing platform to develop closer links with institutional investment platforms. We consider EIS funds to be an increasingly important source of financing for early-stage technology companies and believe Parkwalk's strong links to leading institutional wealth managers and university partners will be beneficial to the Group."
Alastair Kilgour, Co-founder of Parkwalk, said: "The acquisition of Parkwalk by IP Group gives our underlying investors the security of being part of a larger organisation which also brings with it specialist resources and expertise around developing businesses formed around hard science. The strength of IP Group will allow Parkwalk to expand and enhance its EIS fund offerings, helping to boost the UK technology base and returns to investors."
The total maximum consideration payable for Parkwalk by IP Group is GBP20m over a three-year period. The initial consideration comprises GBP5.0m payable in cash, GBP2.5m payable in the form of newly-issued IP Group ordinary shares and GBP2.5m of cash payable in two equal tranches over two years, subject to certain conditions. The remaining GBP10m consideration is payable as GBP5m in cash and GBP5m in IP Group ordinary shares over a three-year period, subject to Parkwalk achieving certain business performance targets.
A change of controller application has been submitted to the Financial Conduct Authority (the "FCA") and final completion of the acquisition is conditional on approval being received from the FCA, such approval being anticipated within a three-month period.|
|Been watching this as well bamboo for a while had a chance at 140 but choose topping up on pfc at 790(sorry o/t what's your thoughts on NBI chart bamboo?If you have time|
|Clear breakout of the Symmetrical Triangle now for minimum tp of 170.
broadwood, The fun and games have started|
|Took some of these on Friday. Price looks to be near support zone.
With Google Ventures awash with spare investment cash, it's hard to ignore the fact that Googles Deep Mind is invovled in this recent fundraising.
Googles interest in Health matters would align quite well with some of the co's in IPO. imo|
|Fun and games today I'm thinking.|
|First human DNA sequence from a handheld in a clinical patient setting - Oxford Nanopore.|
|Weakness isn't reversing. Look at the chart back to 106p 6th December 2013 (year may be wrong as form memory) but I see further falls. Equity realisations from the portfolio are some way off as the market isn't supportive and some holding will need more capital so more money going out or dilution in some - MWG an example. It used to be a top 10 holding.
So - long term fantastic. Short - weak and lower. Medium - don't know - neutral around 130p in my humble opinion.|